AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24691204 — intervention group
Group type: EXPERIMENTAL
Intervention: T-cell activation
Number of subjects: 147
Study 24691204 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic inflammation
Number of subjects: 147
Study 24691204 — intervention group
Group type: EXPERIMENTAL
Intervention: sCD14, hs-CRP, fibrinogen
Number of subjects: 147
Study 24691436 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate (110 mg bid)
Number of subjects: 100
Study 24691436 — intervention group
Group type: COMPARATOR
Intervention: Warfarin (dose-adjusted)
Number of subjects: 100
Study 24692527 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 or 10 mg twice daily
Number of subjects: 4102
Study 24692579 — intervention group
Group type: EXPERIMENTAL
Intervention: Trabectedin 1.3 mg/m(2) as a 3-h i.v. infusion every 3 weeks until progression or intolerance
Number of subjects: 40
Study 24692579 — intervention group
Group type: EXPERIMENTAL
Intervention: Trabectedin
Number of subjects: 40
Study 24692582 — intervention group
Group type: EXPERIMENTAL
Intervention: Computed tomographic coronary angiography (CTA) screening
Number of subjects: 52
Study 24692582 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary angiography
Number of subjects: 52
Study 24692582 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal medical therapy
Number of subjects: 52
Study 24692582 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening questionnaire
Number of subjects: 52
Study 24693532 — intervention group
Group type: EXPERIMENTAL
Intervention: Mag-paDRE program
Number of subjects: 925
Study 24694729 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve implantation (TAVI)
Number of subjects: 697
Study 24695685 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipilimumab administration
Number of subjects: 20
Study 24695882 — intervention group
Group type: EXPERIMENTAL
Intervention: Pertubation of the uterine cavity prior to insemination in 79 patients
Number of subjects: 180
Study 24695882 — intervention group
Group type: COMPARATOR
Intervention: Control group (no pertubation)
Number of subjects: 180
Study 24695882 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 180
Study 24696183 — intervention group
Group type: EXPERIMENTAL
Intervention: [(18) F]VM4-037
Number of subjects: 4
Study 24697160 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted retention strategies including community engagement, interpersonal relationship building, reduction of external barriers, staff capacity building, and external tracing.
Number of subjects: 0
Study 24697160 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (no specific intervention mentioned).
Number of subjects: 0
Study 24697851 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifaximin (275, 550, and 1100 mg twice daily for 2 weeks; 550 mg twice daily for 4 weeks; 550 mg three times daily for 2 weeks)
Number of subjects: 1932
Study 24697851 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifaximin
Number of subjects: 1932
Study 24698176 — intervention group
Group type: EXPERIMENTAL
Intervention: RH-PAT score in adolescents with overweight or obesity
Number of subjects: 27
Study 24698176 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline pulse amplitude in adolescents with overweight or obesity
Number of subjects: 27
Study 24698176 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of baseline pulse amplitude
Number of subjects: 27
Study 24698176 — intervention group
Group type: COMPARATOR
Intervention: RH-PAT score in healthy controls
Number of subjects: 27
Study 24698176 — intervention group
Group type: COMPARATOR
Intervention: Baseline pulse amplitude in healthy controls
Number of subjects: 27
Study 24699276 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive knee-extension strength training (ankle weight cuffs, 3 sets of 10 repetitions)
Number of subjects: 36
Study 24699307 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Number of subjects: 64
Study 24699379 — intervention group
Group type: EXPERIMENTAL
Intervention: Diffuse-trickling GA
Number of subjects: 61
Study 24699462 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with target organ damage (TOD)
Number of subjects: 486
Study 24699462 — intervention group
Group type: EXPERIMENTAL
Intervention: Measurement of peripheral and central blood pressure
Number of subjects: 486
Study 24699462 — intervention group
Group type: EXPERIMENTAL
Intervention: Size of eye fundus arteries and veins
Number of subjects: 486
Study 24699462 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxidative stress
Number of subjects: 486
Study 24699462 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymorphisms in VAV-2 and VAV-3 genes
Number of subjects: 486
Study 24699462 — intervention group
Group type: COMPARATOR
Intervention: Participants without target organ damage (TOD)
Number of subjects: 486
Study 24699474 — intervention group
Group type: EXPERIMENTAL
Intervention: ART (antiretroviral therapy)
Number of subjects: 143
Study 24699910 — intervention group
Group type: EXPERIMENTAL
Intervention: Eribulin mesylate 1.4 mg/m² IV on days 1 and 8 of each 3-week cycle
Number of subjects: 56
Study 24700623 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinician-rated assessment
Number of subjects: 644
Study 24700623 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-report assessment
Number of subjects: 644
Study 24703206 — intervention group
Group type: COMPARATOR
Intervention: Beta-blockers (carvedilol, metoprolol succinate, bisoprolol) at target doses of 50mg, 200mg, and 10mg/day respectively.
Number of subjects: 3759
Study 24703206 — intervention group
Group type: COMPARATOR
Intervention: Beta-blockers (carvedilol, metoprolol succinate, bisoprolol) at target doses.
Number of subjects: 3759
Study 24703920 — intervention group
Group type: EXPERIMENTAL
Intervention: HF with an ICD with appropriate intervention
Number of subjects: 0
Study 24703920 — intervention group
Group type: COMPARATOR
Intervention: HF with an ICD without appropriate intervention
Number of subjects: 0
Study 24703920 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating SCN5A variant levels
Number of subjects: 0
Study 24703920 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating SCN5A variants
Number of subjects: 0
Study 24704179 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of mobile devices and SMS for diet and exercise information
Number of subjects: 12
Study 24704719 — intervention group
Group type: EXPERIMENTAL
Intervention: telaprevir
Number of subjects: 511
Study 24704719 — intervention group
Group type: EXPERIMENTAL
Intervention: boceprevir
Number of subjects: 511
Study 24704719 — intervention group
Group type: EXPERIMENTAL
Intervention: telaprevir or boceprevir
Number of subjects: 511
Study 24704773 — intervention group
Group type: COMPARATOR
Intervention: Asunaprevir 200 mg twice daily in mild hepatic impairment
Number of subjects: 34
Study 24704773 — intervention group
Group type: COMPARATOR
Intervention: Asunaprevir 200 mg twice daily in moderate hepatic impairment
Number of subjects: 34
Study 24704773 — intervention group
Group type: COMPARATOR
Intervention: Asunaprevir 200 mg twice daily in severe hepatic impairment
Number of subjects: 34
Study 24704921 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative interviews with patients recovering from IE
Number of subjects: 11
Study 24704921 — intervention group
Group type: EXPERIMENTAL
Intervention: Support from relatives and healthcare professionals
Number of subjects: 11
Study 24704921 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical, cognitive, and emotional experiences post-IE
Number of subjects: 11
Study 24705186 — intervention group
Group type: EXPERIMENTAL
Intervention: Radotinib 400 mg twice daily for 12 cycles
Number of subjects: 77
Study 24705452 — intervention group
Group type: EXPERIMENTAL
Intervention: EIAV-CMV-MYO7A (UshStat)
Number of subjects: 1
Study 24705452 — intervention group
Group type: EXPERIMENTAL
Intervention: EIAV-CMV-GFP/MYO7A vectors
Number of subjects: 1
Study 24705452 — intervention group
Group type: EXPERIMENTAL
Intervention: UshStat
Number of subjects: 1
Study 24705452 — intervention group
Group type: COMPARATOR
Intervention: EIAV-CMV-Null (control)
Number of subjects: 1
Study 24705452 — intervention group
Group type: COMPARATOR
Intervention: EIAV-CMV-GFP
Number of subjects: 1
Study 24705452 — intervention group
Group type: COMPARATOR
Intervention: EIAV-RK-GFP (photoreceptor specific)
Number of subjects: 1
Study 24705492 — intervention group
Group type: EXPERIMENTAL
Intervention: First-line combined fludarabine, cyclophosphamide, and rituximab (FCR)
Number of subjects: 237
Study 24705867 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine
Number of subjects: 504
Study 24705867 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulant
Number of subjects: 504
Study 24705867 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of both treatments
Number of subjects: 504
Study 24705867 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-rated GIPD
Number of subjects: 504
Study 24705867 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician-rated GIPD
Number of subjects: 504
Study 24705867 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-rated GIPD
Number of subjects: 504
Study 24705867 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-rated EESC
Number of subjects: 504
Study 24705867 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-rated EESC
Number of subjects: 504
Study 24705975 — intervention group
Group type: EXPERIMENTAL
Intervention: Pazopanib (400 or 600 mg daily)
Number of subjects: 25
Study 24705975 — intervention group
Group type: EXPERIMENTAL
Intervention: Pazopanib (600 mg) on Day 15 with bevacizumab (7.5 mg/kg iv)
Number of subjects: 25
Study 24705975 — intervention group
Group type: EXPERIMENTAL
Intervention: Pazopanib (600 mg) on Day 16 (24h after bevacizumab)
Number of subjects: 25
Study 24705975 — intervention group
Group type: EXPERIMENTAL
Intervention: Pazopanib (600 mg)
Number of subjects: 25
Study 24707402 — intervention group
Group type: EXPERIMENTAL
Intervention: H. pylori eradication therapy (lansoprazole 30 mg twice daily, amoxicillin 0.75 g twice daily, clarithromycin 250 mg twice daily for 14 days)
Number of subjects: 59
Study 24707402 — intervention group
Group type: EXPERIMENTAL
Intervention: H. pylori stool antigen test positive patients
Number of subjects: 59
Study 24707402 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline proteinuria levels
Number of subjects: 59
Study 24707402 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 59
Study 24708624 — intervention group
Group type: EXPERIMENTAL
Intervention: HLA-A*2402-restricted multi-peptide vaccine combined with CRT (radiotherapy 60 Gy, cisplatin 40 mg/m², 5-fluorouracil 400 mg/m²)
Number of subjects: 11
Study 24708667 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha fetoprotein DNA prime and adenovirus boost vaccination (3 plasmid DNA injections followed by 1 AdV injection, all intramuscularly)
Number of subjects: 2
Study 24708667 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha fetoprotein DNA prime and adenovirus boost vaccination
Number of subjects: 2
Study 24708677 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based counseling program based on the 'patient journey' model
Number of subjects: 80
Study 24708677 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control (WLC)
Number of subjects: 80
Study 24708726 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrative Medicine (IM) intervention at UAIHC
Number of subjects: 500
Study 24708726 — intervention group
Group type: COMPARATOR
Intervention: Matched control groups
Number of subjects: 500
Study 24708726 — intervention group
Group type: COMPARATOR
Intervention: Self-report measures
Number of subjects: 500
Study 24708726 — intervention group
Group type: EXPERIMENTAL
Intervention: Fidelity data from clinic patients and personnel
Number of subjects: 500
Study 24708726 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative study of 8 patients
Number of subjects: 500
Study 24709691 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressants
Number of subjects: 457
Study 24709811 — intervention group
Group type: EXPERIMENTAL
Intervention: Brimonidine 0.15% for 8 weeks
Number of subjects: 46
Study 24709811 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 46
Study 24710133 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone/prednisolone with salbutamol and cointerventions (ipratropium bromide)
Number of subjects: 1008
Study 24710654 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous subhairline electroencephalographic (cEEG) monitoring
Number of subjects: 101
Study 24710768 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin-based chemotherapy plus cetuximab (weekly cetuximab plus 3-week cycles of cisplatin/5-FU for up to 6 cycles)
Number of subjects: 68
Study 24710768 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin-based chemotherapy plus cetuximab
Number of subjects: 68
Study 24710915 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet emphasizing dietary pulse intake (median dose of 130 g/d)
Number of subjects: 1037
Study 24710915 — intervention group
Group type: COMPARATOR
Intervention: Isocaloric diet without dietary pulses
Number of subjects: 1037
Study 24711212 — intervention group
Group type: EXPERIMENTAL
Intervention: Bosutinib
Number of subjects: 288
Study 24711230 — intervention group
Group type: EXPERIMENTAL
Intervention: Progression risk score based on biological markers (CD38, ZAP-70, IGHV mutational status)
Number of subjects: 468
Study 24711230 — intervention group
Group type: EXPERIMENTAL
Intervention: Progression risk score applied to Rai 0 cases
Number of subjects: 468
Study 24711230 — intervention group
Group type: EXPERIMENTAL
Intervention: Cox multivariate analysis including Rai stage, absolute lymphocyte count, progression risk score, and β-2 microglobulin
Number of subjects: 468
Study 24711549 — intervention group
Group type: EXPERIMENTAL
Intervention: Lapatinib (7,000 mg per day in twice-daily dosing)
Number of subjects: 40
Study 24711549 — intervention group
Group type: EXPERIMENTAL
Intervention: Lapatinib with ketoconazole (to increase exposure)
Number of subjects: 40
Study 24711549 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent dosing of lapatinib
Number of subjects: 40
Study 24711551 — intervention group
Group type: EXPERIMENTAL
Intervention: hu14.18K322A (60 mg/m(2) per day for 4 days)
Number of subjects: 38
Study 24711551 — intervention group
Group type: EXPERIMENTAL
Intervention: hu14.18K322A
Number of subjects: 38
Study 24711599 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-linked supervision approach
Number of subjects: 824
Study 24711599 — intervention group
Group type: COMPARATOR
Intervention: Facility-only supervision approach
Number of subjects: 824
Study 24712435 — intervention group
Group type: EXPERIMENTAL
Intervention: Ecallantide
Number of subjects: 521
Study 24712435 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 521
Study 24712447 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (RIPC) - four 5 minute cycles of upper limb ischemia/reperfusion
Number of subjects: 35
Study 24712447 — intervention group
Group type: COMPARATOR
Intervention: Control (no RIPC)
Number of subjects: 35
Study 24712564 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic human GIP (20 ng · kg(-1) · min(-1))
Number of subjects: 92
Study 24712564 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline 0.9% NaCl)
Number of subjects: 92
Study 24712564 — intervention group
Group type: EXPERIMENTAL
Intervention: GIP bolus in C57BL/6 mice
Number of subjects: 92
Study 24712564 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral glucose tolerance test
Number of subjects: 92
Study 24712976 — intervention group
Group type: EXPERIMENTAL
Intervention: TF-CBT
Number of subjects: 135
Study 24712976 — intervention group
Group type: COMPARATOR
Intervention: TAU
Number of subjects: 135
Study 24713455 — intervention group
Group type: EXPERIMENTAL
Intervention: CHADS₂ score 1-2
Number of subjects: 297
Study 24713455 — intervention group
Group type: EXPERIMENTAL
Intervention: CHADS₂ score ≥ 3
Number of subjects: 297
Study 24713455 — intervention group
Group type: EXPERIMENTAL
Intervention: CHADS₂ score
Number of subjects: 297
Study 24714268 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic endoscopy
Number of subjects: 201
Study 24714268 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood product transfusions
Number of subjects: 201
Study 24714268 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton pump inhibitors administration
Number of subjects: 201
Study 24714268 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncontrolled bleeding or rebleeding
Number of subjects: 201
Study 24714268 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-look endoscopy
Number of subjects: 201
Study 24714268 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiographic intervention
Number of subjects: 201
Study 24714268 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical intervention
Number of subjects: 201
Study 24714268 — intervention group
Group type: EXPERIMENTAL
Intervention: Mortality during hospitalization
Number of subjects: 201
Study 24714268 — intervention group
Group type: EXPERIMENTAL
Intervention: Mortality during 30-day post-hospitalization period
Number of subjects: 201
Study 24714488 — intervention group
Group type: EXPERIMENTAL
Intervention: High-grade rejection (≥3A)
Number of subjects: 48
Study 24714488 — intervention group
Group type: COMPARATOR
Intervention: None/mild rejection (0, 1A/1B, or 2)
Number of subjects: 48
Study 24714750 — intervention group
Group type: EXPERIMENTAL
Intervention: Ombrabulin (35 mg/m²) with docetaxel (75 mg/m²)
Number of subjects: 58
Study 24714750 — intervention group
Group type: EXPERIMENTAL
Intervention: Ombrabulin (30 mg/m²) with docetaxel (100 mg/m²)
Number of subjects: 58
Study 24714750 — intervention group
Group type: EXPERIMENTAL
Intervention: Ombrabulin (42 mg/m²) with docetaxel (75 mg/m²)
Number of subjects: 58
Study 24714750 — intervention group
Group type: EXPERIMENTAL
Intervention: Ombrabulin (35 mg/m²) with docetaxel (100 mg/m²)
Number of subjects: 58
Study 24714750 — intervention group
Group type: EXPERIMENTAL
Intervention: Ombrabulin (30 mg/m²) with docetaxel (75 mg/m²)
Number of subjects: 58
Study 24714750 — intervention group
Group type: EXPERIMENTAL
Intervention: Ombrabulin (100 mg/m²) with docetaxel (100 mg/m²)
Number of subjects: 58
Study 24714778 — intervention group
Group type: EXPERIMENTAL
Intervention: Cediranib 45 mg/day
Number of subjects: 34
Study 24714806 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific ceramide, phosphatidylcholine and phosphatidylethanolamine lipids
Number of subjects: 0
Study 24714806 — intervention group
Group type: EXPERIMENTAL
Intervention: Lysophosphatidylcholine, lysophosphatidylethanolamine, phosphatidylcholine and phosphatidylethanolamine lipids
Number of subjects: 0
Study 24714806 — intervention group
Group type: EXPERIMENTAL
Intervention: LPC a C18:1 and PE ae C40:6
Number of subjects: 0
Study 24714806 — intervention group
Group type: EXPERIMENTAL
Intervention: CRP, TNF-α, resistin and MCP-1
Number of subjects: 0
Study 24714806 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-8
Number of subjects: 0
Study 24714973 — intervention group
Group type: EXPERIMENTAL
Intervention: Zalutumumab (weekly infusions, individually titrated to a grade 2 skin rash)
Number of subjects: 90
Study 24715201 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D movement correction method for CT brain perfusion (CTP) acquisition
Number of subjects: 35
Study 24715201 — intervention group
Group type: COMPARATOR
Intervention: Original CTP data
Number of subjects: 35
Study 24715548 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone (15-30 mg/day) for 8 weeks
Number of subjects: 34
Study 24716469 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK933776 1 mg/kg
Number of subjects: 18
Study 24716469 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK933776 3 mg/kg
Number of subjects: 18
Study 24716469 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK933776 6 mg/kg
Number of subjects: 18
Study 24716542 — intervention group
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel (260 mg/m² i.v. on day 1 of each 21-day cycle)
Number of subjects: 56
Study 24716655 — intervention group
Group type: EXPERIMENTAL
Intervention: Florbetapir F 18 (amyloid imaging agent)
Number of subjects: 31
Study 24716655 — intervention group
Group type: EXPERIMENTAL
Intervention: 18F-AV-133 (florbenazine, VMAT2 density marker)
Number of subjects: 31
Study 24716655 — intervention group
Group type: EXPERIMENTAL
Intervention: Florbenazine binding in DLB patients
Number of subjects: 31
Study 24717109 — intervention group
Group type: EXPERIMENTAL
Intervention: Ocaratuzumab 375 mg/m(2) weekly for 4 weeks
Number of subjects: 50
Study 24717325 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of plaques in multi-detector computed tomography
Number of subjects: 0
Study 24717340 — intervention group
Group type: EXPERIMENTAL
Intervention: Added sugars consumption
Number of subjects: 320
Study 24717340 — intervention group
Group type: COMPARATOR
Intervention: Sodium intake
Number of subjects: 320
Study 24717340 — intervention group
Group type: COMPARATOR
Intervention: Dietary fat intake
Number of subjects: 320
Study 24717362 — intervention group
Group type: EXPERIMENTAL
Intervention: 25-hydroxyvitamin D (25(OH)D)
Number of subjects: 239
Study 24717362 — intervention group
Group type: EXPERIMENTAL
Intervention: 25-hydroxyvitamin D (25(OH)D) ≥ ∼26 μg/L (65.0 pmol/L)
Number of subjects: 239
Study 24717362 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin-like growth factor-1 (IGF-1)
Number of subjects: 239
Study 24717379 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium in monotherapy
Number of subjects: 300
Study 24717379 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic medication changed by psychiatrist
Number of subjects: 300
Study 24717379 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic medication stopped by patient
Number of subjects: 300
Study 24717379 — intervention group
Group type: COMPARATOR
Intervention: General relapse data
Number of subjects: 300
Study 24717379 — intervention group
Group type: COMPARATOR
Intervention: Relapse correlation with index episode
Number of subjects: 300
Study 24717420 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese group (n=92)
Number of subjects: 92
Study 24717420 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=49)
Number of subjects: 92
Study 24717624 — intervention group
Group type: EXPERIMENTAL
Intervention: High-resolution CT classified as usual interstitial pneumonia
Number of subjects: 315
Study 24717624 — intervention group
Group type: EXPERIMENTAL
Intervention: High-resolution CT classified as possible usual interstitial pneumonia
Number of subjects: 315